ArticleJournal of diabetes science and technology2020
Benefits and Limitations of MARD as a Performance Parameter for Continuous Glucose Monitoring in the Interstitial Space.
Article in Journal of diabetes science and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications.Reviews in endocrine & metabolic disorders · 2024Pooled it
- Clinical validation of continuous glucose monitoring in glycemic management of critically ill sepsis patients: A prospective randomized clinical study.The Journal of international medical research · 2026Trial
- The Effect of Insulin Degludec Versus Insulin Glargine U100 on Glucose Metrics Recorded During Continuous Glucose Monitoring in People With Type 1 Diabetes and Recurrent Nocturnal Severe Hypoglycemia.Journal of diabetes science and technology · 2025Trial
- Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept Study.Journal of diabetes science and technology · 2024Trial
- Trial
- CGM Accuracy in a Fragmented Regulatory Landscape: A Commentary on Harmonisation and Recent Evidence.Diabetes, obesity & metabolism · 2026Article
- Regulatory standardisation to improve the safety of continuous glucose monitoring systems in Australia and New Zealand: joint ADS/ADEA/ADIPS/ANZSPED/NZSSD statement.Internal medicine journal · 2026Article
- Consumer Smartwatch Technology in Health and Performance Research: Validity, Limitations, and Real-World Applications.Sensors (Basel, Switzerland) · 2026Review
- International clinical opinion on transparency, standardisation, and calibration alignment in the performance evaluation of systems for continuous glucose monitoring.Diabetes, obesity & metabolism · 2026Review
- Optimizing Continuous Glucose Monitoring Adoption in India: From Current Challenges to Future Solutions.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Simultaneous Use of Continuous Glucose Monitoring (CGM) Systems and the Remote Electrical Neuromodulation (REN) Wearable for Patients with Comorbid Diabetes and Migraine: An Interventional Single-Arm Compatibility Study.Journal of clinical medicine · 2026Article
- Diabetes Monitoring in Pregnant Women with Type 1 Diabetes: Capillary Blood Glucose or Interstitial Fluid Glucose? A Case Control Study.Nutrition and metabolic insights · 2026Article
- Clinical validation of noninvasive blood glucose measurements by midinfrared spectroscopy.Communications medicine · 2025Article
- Revolutionizing Hypoglycemia Management in Long-Term Care: Lessons Learned From a Pilot Quality Improvement Initiative Using Continuous Glucose Monitoring.JMIR diabetes · 2025Article
- Accuracy of continuous glucose monitoring during noncardiac surgery: a prospective, blinded observational multicentre cohort study.British journal of anaesthesia · 2025Observational
- Smart closed-loop drug delivery systems.Nature reviews bioengineering · 2025Article
- Optimizing Perioperative Glycaemic Control with Continuous Glucose Monitoring in Pregestational Diabetes: Feasibility and Comparative Analysis of Two Systems: A Pilot Study.Journal of clinical medicine · 2025Article
- Scoping Review-Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions.Journal of diabetes science and technology · 2025Review
- Continuous Glucose Monitoring Systems Can Meet the Challenge of Glucose Management and Beyond in Individuals with Type 2 Diabetes: An Expert Multidisciplinary Position.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-quality performance of medical devices for glucose monitoring is important for a safe and efficient usage of this diagnostic option by patients with diabetes. The mean absolute relative difference (MARD) parameter is used most often to characterize the measurement performance of systems for continuous glucose monitoring (CGM). Calculation of this parameter is relatively easy and comparison of the MARD numbers between different CGM systems appears to be straightforward on the first glance. However, a closer look reveals that a number of complex aspects make interpretation of the MARD numbers provided by the manufacturer for their CGM systems difficult. In this review, these aspects are discussed and considerations are made for a systematic and appropriate evaluation of the MARD in clinical trials. The MARD should not be used as the sole parameter to characterize CGM systems, especially when it comes to nonadjunctive usage of such systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.